Anthony Turpin
Hôpital Claude Huriez(FR)
Publications by Year
Research Areas
Cholangiocarcinoma and Gallbladder Cancer Studies, Colorectal Cancer Treatments and Studies, Pancreatic and Hepatic Oncology Research, Gastric Cancer Management and Outcomes, Peptidase Inhibition and Analysis
Most-Cited Works
- → Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer(2022)295 cited
- → Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)(2020)164 cited
- → Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial(2022)122 cited
- → Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort(2023)83 cited
- → Imaging for Metastasis in Prostate Cancer: A Review of the Literature(2020)67 cited
- → Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial(2021)66 cited
- → Two cases of immune thrombocytopenia associated with pembrolizumab(2015)55 cited
- → FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).(2018)53 cited
- → Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies(2022)52 cited
- → Bone Metastasis: Current State of Play(2019)49 cited